Blocking a growth signal helped virus therapy and radiation in animal tests
Original title: Overcoming IGF1R-mediated resistance to oncolytic HSV1 and radiotherapy via triple combination therapy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in cells in a dish and in mice.
The short version
In mice, adding a drug that blocks one growth signal made cancer-killing virus therapy and radiation work better.
What was studied. Researchers tested a cancer-killing herpes virus, radiation, and a drug that blocks a growth signal called IGF1R. They used breast cancer cells and glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells in the lab, and mice with those tumors.
What they found. The virus switched on the IGF1R growth signal, and that signal helped tumor cells keep growing. When the virus and radiation were given together, tumors that resisted treatment switched on IGF1R and a second signal called YAP1 even more strongly. Adding the IGF1R blocker to both shut off YAP1 and helped the mice live longer.
What this means, and what it doesn't
What it could mean: This gives one possible reason tumors fight back after virus therapy and radiation. It gives researchers a reason to test this three-part combination in people.
What it doesn't mean: This does not mean a new treatment is ready. The work was done in cells in a dish and in mice, not in people. No one has tested this combination in patients. It is not a cure, and it is not something a doctor can offer you now. Many treatments that work in mice do not work in people.
Source: PubMed, July 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.